

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM363000

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
Theraclone Sciences, Inc.		10/01/2015	CORPORATION: DELAWARE
RECEIVING PARTY DATA			
Name:	MidCap Financial Trust		
Street Address:	c/o MidCap Financial Services, LLC, as servicer		
Internal Address:	7255 Woodmont Avenue, Suite 200		
City:	Bethesda		
State/Country:	MARYLAND		
Postal Code:	20814		
Entity Type:	Statutory Trust: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	3680336	I-STAR	
Registration Number:	4388327	THERACLONE SCIENCES	
Registration Number:	3952304	THERACLONE SCIENCES	
CORRESPONDENCE DATA			
Fax Number:	4044435697		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	404-443-5648		
Email:	lallen@mcguirewoods.com		
Correspondent Name:	Kimberly Scott, Esq.		
Address Line 1:	McGuireWoods LLP		
Address Line 2:	1230 Peachtree Street, N.E., Suite 2100		
Address Line 4:	Atlanta, GEORGIA 30309		
ATTORNEY DOCKET NUMBER:	2061695-0014 THERACLONE		
NAME OF SUBMITTER:	Latosha E. Allen		
SIGNATURE:	/Latosha E. Allen/		
DATE SIGNED:	11/19/2015		
Total Attachments: 30			

OP \$90.00 3680336

source=Theraclone - IP Security Agreement #page1.tif
source=Theraclone - IP Security Agreement #page2.tif
source=Theraclone - IP Security Agreement #page3.tif
source=Theraclone - IP Security Agreement #page4.tif
source=Theraclone - IP Security Agreement #page5.tif
source=Theraclone - IP Security Agreement #page6.tif
source=Theraclone - IP Security Agreement #page7.tif
source=Theraclone - IP Security Agreement #page8.tif
source=Theraclone - IP Security Agreement #page9.tif
source=Theraclone - IP Security Agreement #page10.tif
source=Theraclone - IP Security Agreement #page11.tif
source=Theraclone - IP Security Agreement #page12.tif
source=Theraclone - IP Security Agreement #page13.tif
source=Theraclone - IP Security Agreement #page14.tif
source=Theraclone - IP Security Agreement #page15.tif
source=Theraclone - IP Security Agreement #page16.tif
source=Theraclone - IP Security Agreement #page17.tif
source=Theraclone - IP Security Agreement #page18.tif
source=Theraclone - IP Security Agreement #page19.tif
source=Theraclone - IP Security Agreement #page20.tif
source=Theraclone - IP Security Agreement #page21.tif
source=Theraclone - IP Security Agreement #page22.tif
source=Theraclone - IP Security Agreement #page23.tif
source=Theraclone - IP Security Agreement #page24.tif
source=Theraclone - IP Security Agreement #page25.tif
source=Theraclone - IP Security Agreement #page26.tif
source=Theraclone - IP Security Agreement #page27.tif
source=Theraclone - IP Security Agreement #page28.tif
source=Theraclone - IP Security Agreement #page29.tif
source=Theraclone - IP Security Agreement #page30.tif

INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Intellectual Property Security Agreement is entered into as of the 1st day of October 2015 by and among MIDCAP FINANCIAL TRUST, a Delaware statutory trust, (“Agent”), THERACLONE SCIENCES, INC., a Delaware corporation (the “Grantor”).

RECITALS

A. The Lenders (as defined below) have agreed to make certain advances of money and to extend certain financial accommodation to Grantor (the “Credit Extensions”) in the amounts and manner set forth in that certain Credit and Security Agreement by and among Agent, the financial institutions party thereto from time to time (collectively, the “Lenders”), and Grantor, dated as March 11, 2013 (as the same may be amended, modified or supplemented from time to time, the “Credit Agreement”; capitalized terms used herein are used as defined in the Credit Agreement). The Lenders are willing to make the Credit Extensions to Grantor, but only upon the condition, among others, that Grantor shall grant to Agent, for the ratable benefit of the Lenders, a security interest in certain Copyrights, Trademarks, Patents, and Mask Works (as each term is described below) to secure the obligations of Grantor under the Credit Agreement.

B. Pursuant to the terms of the Credit Agreement, Grantor has granted to Agent, for the ratable benefit of the Lenders, a security interest in all of Grantor’s right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral (as specifically defined in the Credit Agreement).

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of its obligations under the Credit Agreement, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

To secure its obligations under the Credit Agreement, each Grantor grants and pledges to Agent, for the ratable benefit of the Lenders, a security interest in all of such Grantor’s right, title and interest in, to and under its intellectual property (all of which shall collectively be called the “Intellectual Property Collateral”), including, without limitation, the following:

(a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the “Copyrights”);

(b) Any and all trade secrets, and any and all intellectual property rights in computer software and computer software products now or hereafter existing, created, acquired or held;

(c) Any and all design rights that may be available to such Grantor now or hereafter existing, created, acquired or held;

(d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “**Patents**”);

(e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantor connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “**Trademarks**”);

(f) All mask works or similar rights available for the protection of semiconductor chips, now owned or hereafter acquired, including, without limitation those set forth on Exhibit D attached hereto (collectively, the “**Mask Works**”);

(g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;

(h) All licenses or other rights to use any of the Copyrights, Patents, Trademarks, or Mask Works and all license fees and royalties arising from such use to the extent permitted by such license or rights;

(i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, Patents, or Mask Works; and

(j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

This security interest is granted in conjunction with the security interest granted to Agent, for the ratable benefit of the Lenders, under the Credit Agreement. The rights and remedies of Agent with respect to the security interest granted hereby are in addition to those set forth in the Credit Agreement and the other Financing Documents, and those which are now or hereafter available to Agent as a matter of law or equity. Each right, power and remedy of Agent provided for herein or in the Credit Agreement or any of the Financing Documents, or now or hereafter existing at law or in equity shall be cumulative and concurrent and shall be in addition to every right, power or remedy provided for herein and the exercise by Agent of any one or more of the rights, powers or remedies provided for in this Intellectual Property Security Agreement, the Credit Agreement or any of the other Financing Documents, or now or hereafter existing at law or in equity, shall not preclude the simultaneous or later exercise by any person, including Agent, of any or all other rights, powers or remedies.

[Remainder of page intentionally blank; signature page follows.]


IN WITNESS WHEREOF, the parties have caused this Intellectual Property Security Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

Address of Grantor:

THERACLONE SCIENCES, INC.

Theraclone Sciences, Inc.
1124 Columbia Street, Suite 300
Seattle, Washington 98104
Attention: Russ Hawkinson
Fax: (206) 805-1699
E-Mail: RHawkinson@theraclone-sciences.com

By:  (SEAL)
Name: Russ Hawkinson
Title: CFO

THERACLONE SCIENCES, INC.
INTELLECTUAL PROPERTY SECURITY AGREEMENT
SIGNATURE PAGE

TRADEMARK
REEL: 005672 FRAME: 0731

AGENT:


Address of Agent:

MidCap Financial Trust
c/o MidCap Financial Services, LLC, as servicer
7255 Woodmont Ave, Suite 200
Bethesda, MD 20814
Attn: Account Manager for Theraclone transaction
Facsimile: 301-941-1450
Email: notices@midcapfinancial.com

MIDCAP FINANCIAL TRUST

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By:  (SEAL)

Name: Maurice Amsellem
Title: Authorized Signatory

Theraclone Sciences, Inc.
Intellectual Property Security Agreement
Signature Page

TRADEMARK
REEL: 005672 FRAME: 0732

EXHIBIT A

Copyrights

None.

EXHIBIT B

Patents

[See attached]

THE RACLONE CASE LIST

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-003/N01AU 316188-2019	37418- 503N01AU	PCT	Granted	2008321016 (Patent No. 2008321016)	12-Nov-2008	Australia	Compositions And Methods For The Therapy And Diagnosis Of Influenza	Influenza M2e: Compositions and Methods for the Therapy and Diagnosis of Influenza: Encompasses antibodies 8110, 21B15 and 23K12. Also encompasses epitopes linear and non-linear epitopes of the M2e polypeptide, and specifically, comprises the amino-terminal region of the M2e polypeptide, the amino acid at position 2, 5, and 6 of the M2e polypeptide, wherein amino acid position numbers are in accordance with MSLITEVETPTRNNEWGCR CNDSSD (SEQ ID NO. 1), wherein the amino acid at position 2 is a serine; position 5 is a threonine; and position 6 is a glutamic acid, and wherein said epitope wholly or partially includes the amino acid sequence SLLTEV (SEQ ID NO. 42). (Claims to 8110 are elected)	None	
THHR-003/N01BR 316188-2021	37418- 503N01BR	PCT	Pending	PI0820053-0	12-Nov-2008	Brazil	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01CA 316188-2022	37418- 503N01CA	PCT	Pending	2705555	12-Nov-2008	Canada	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Response to Office Action	09/24/2015 (Final)
THHR-003/N01CN 316188-2024	37418- 503N01CN	PCT	Granted	200880123932.8	12-Nov-2008	China (People's Republic)	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/D01CN 316188-2013	37418- 503D01CN	DIV	Pending	201410103093.0	12-Nov-2008	China (People's Republic)	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-003/N01IEP 316188-2027	37418- 503N01IEP	PCT	Granted	08850112.7 (EP Pub. No. 2220116)	12-Nov-2008	European Patent Convention (Validated in Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland , and UK)	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01HK 316188-2032	37418- 503N01HK	REG	Granted	11101919.3 (HK Patent No. HK1147767)	12-Nov-2008	Hong Kong	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Maintenance Fee Due	10/12/2016 11/12/2016
THHR-003/D01HK 316188-2181	N/A	REG	Pending	15102928.6	12-Nov-2008	Hong Kong	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01IN 316188-2035	37418- 503N01IN	PCT	Published	1815/KOLNP/201 0	12-Nov-2008	India	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01IL 316188-2034	37418- 503N01IL	PCT	Pending	205705	12-Nov-2008	Israel	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Response to Office Action	10/3/2015
THHR-003/N01JP 316188-2037	37418- 503N01JP	PCT	Granted	2010-527260 (Patent No. 4932940)	12-Nov-2008	Japan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-003/D01JP 316188-2014	37418- 503D01JP	DIV	Granted	2011-105659 (Patent No. 5623332)	12-Nov-2008	Japan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01KR 316188-2038	37418- 503N01KR	PCT	Pending	10-2010-7012975	12-Nov-2008	Korea, Republic of	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01MX 316188-2039	37418- 503N01MX	PCT	Granted	MX/a/2010/00524 4 (Patent No. 312017)	12-Nov-2008	Mexico	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01NZ 316188-2042	37418- 503N01NZ	PCT	Granted	585500 (Patent No. 585500)	12-Nov-2008	New Zealand	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/N01SG 316188-2045	37418- 503N01SG	PCT	Granted	201003325-6 (Patent No. 161495)	12-Nov-2008	Singapore	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/001TW 316188-2006	37418- 503001TW	ORD	Published	98138407	12-Nov-2009	Taiwan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/D01TW 316188-2177	N/A	DIV	Pending	103141976	12-Nov-2009	Taiwan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/001US 316188-2007	37418- 503001US	ORD	Granted	12/269781 (Patent No. 8,057,796)	12-Nov-2008	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHR-003/C01US 316188-2010	37418- 503C01US	CON	Granted	13/215841 (Patent No. 8,460,671)	23-Aug-2011	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-003/C02US 316188-2011	37418- 503C02US	CON	Published	13/914380	10-Jun-2013	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Response to Office Action Due	08/08/2015 (Initial) 11/08/2015 (Final)
THHR-003/D01US 316188-2016	37418- 503D01US	DIV	Granted	12/726297 (Patent No. 8,114,402)	17-Mar-2010	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza	Influenza M2e: Identical to disclosure of USSN 12/269781 (claims to 23K12 are elected).	None	
THHR-003/D02US 316188-2017	37418- 503D02US	DIV	Published	13/772976	21-Feb-2013	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza	Influenza M2e: Identical to 503 disclosure with addition of longer sequences for 8110 and 23K12. Incorporates PNAS manuscript. This is a DIV of USSN 12/795618 (37418-503002US).	None	
THHR-004/N01AU 316188-2056	37418- 504N01AU	PCT	Allowed	2009223688	10-Mar-2009	Australia	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHR-004/D01AU 316188-2180	N/A	DIV	Pending	2015201280	10-Mar-2009	Australia	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections	HCMV: Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus. Encompasses antibodies 2E10, 2MH6, 2N9, 3C21, 4P12, 5P9, and 9C16. Further encompasses epitopes of the glycoprotein b (gpB) envelope protein of the CMV virus, and specifically, wherein said epitope comprises the antigenic determinant 2 site 1 of gpB, gp116.	None	
THHR-004/N01CA 316188-2057	37418- 504N01CA	PCT	Pending	2718878	10-Mar-2009	Canada	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHR-004/N01CN 316188-2058	37418- 504N01CN	PCT	Granted	200980116708.0	10-Mar-2009	China (People's Republic)	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-004/N01HEP 316188-2059	37418- 504N01HEP	PCT	Allowed	097200323 (EP Pub. No. 2257571)	10-Mar-2009	European Patent Convention	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		Power of Attorney	8/3/2015
THHER-004/N01HK 316188-2060	37418- 504N01HK	REG	Published	111054233	10-Mar-2009	Hong Kong	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHER-004/N01HN 316188-2062	37418- 504N01HN	PCT	Published	3400/KOLNP/201 0	10-Mar-2009	India	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHER-004/N01HL 316188-2061	37418- 504N01HL	PCT	Pending	208086	10-Mar-2009	Israel	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHER-004/D01HL 316188-2178	N/A	DIV	Pending	236601	10-Mar-2009	Israel	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		Response to Office Action due	10/23/15
THHER-004/N01JP 316188-2063	37418- 504N01JP	PCT	Granted	2010-550824 (Pat. No. 5544309)	10-Mar-2009	Japan	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-004/D01JP 316188-2054	37418- 504D01JP	PCT	Pending	2013-131336	10-Mar-2009	Japan	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHER-004/N01MX 316188-2064	37418- 504N01MX	PCT	Granted	MX/2010/00988 5 (Patent No. 314239)	10-Mar-2009	Mexico	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus Infections		None	
THHER-004/001US 316188-2050	37418- 504001US	ORD	Granted	12/401585 (Patent No. 7,982,012)	10-Mar-2009	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus	Same disclosure as other 504 applications (claims encompass 2N9 antibody)	None	
THHER-004/C01US 316188-2052	37418- 504C01US	CON	Granted	13/109632 (Patent No. 8,268,309)	17-May-2011	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus	Same disclosure as USSN 12/401585.	None	
THHER-004/C02US 316188-2053	37418- 504C02US	CON	Granted	13/486569 (Patent No. 8,852,594)	01-Jun-2012	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus	Same disclosure as USSN 12/401585 and 13/109632.	None	
THHER-004/C03US 316188-2171	N/A	CON	Pending	14/323,537	03-Jul-2014	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Cytomegalovirus	Same disclosure as USSN 12/401585, 13/109632, and 13/486569.	Response to Restriction Requirement due	8/5/15 (Initial) 12/5/15 (final)
THHER-006/N01AU 316188-2081	37418- 506N01AU	PCT	Accepted	2009314091	12-Nov-2009	Australia	Human M2E Peptide Immunogens	Influenza M2e peptide immunogens: Human M2e Vaccine Immunogens:	None	
THHER-006/N01CA 316188-2082	37418- 506N01CA	PCT	Pending	2743306	12-Nov-2009	Canada	Human M2E Peptide Immunogens	Encompasses peptide immunogens that are effective and capable of inducing	Sequence Listing due	9/4/2015

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-006/N01EP 316188-2083	37418- 506N01EP	PCT	Published	097526768 (EP Pub. No. 2346529)	12-Nov-2009	European Patent Convention	Human M2E Peptide Immunogens	antibodies against influenza A virus to prevent infection by the virus. For example, a peptide immunogen of this invention is represented by the following formula: $[Xaa]_m-Xaa^1-Xaa^2-Xaa^3-Xaa^4-Xaa^5-[Xaa]_n-[Xaa^7]_p-[Xaa^8-Xaa^9-Xaa^{10}-Xaa^{11}-Xaa^{12}]_q$ wherein, m, p and q are independently 0 or 1, n is any number between 0 and 4, Xaa ⁰ is any amino acid, preferably C; Xaa ¹ is any amino acid, preferably V or C; Xaa ² is any amino acid, preferably E; Xaa ³ is any amino acid not including proline, preferably G or A; Xaa ⁴ -Xaa ⁵ -Xaa ⁶ -Xaa ⁷ -Xaa ⁸ -Xaa ⁹ -Xaa ¹⁰ -Xaa ¹¹ -Xaa ¹² is S-L-L-T-E or a peptide having a single substitution to the sequence S-L-L-T-E (SEQ ID NO: 47), the substitution selected from the group consisting of: Xaa ¹ is C or T; Xaa ² is A, C, F or K; Xaa ³ is A, C, E, F, I, K, M, Q, S, T or V, and Xaa ⁴ is D or C.	Deadline to Pay Grant fees (and file translations of claims)	11/1/2015
THHR-006/N01HK 316188-2084	37418- 506001HK	REG	Published	12100695	12-Nov-2009	Hong Kong	Human M2E Vaccine Immunogens		None	
THHR-006/N01JP 316188-2085	37418- 506N01JP	PCT	Published	2011-536450	12-Nov-2009	Japan	Human M2E Vaccine Immunogens		None	
THHR-006/D01JP 316188-2168	N/A	DIV	Pending	2014-106974	12-Nov-2009	Japan	Human M2E Vaccine Immunogens		None	
THHR-006/001US 316188-2078	37418- 506001US	ORD	Granted	12/617243 (Patent No. 8,329,188)	12-Nov-2009	United States of America	Human M2E Peptide Immunogens		None	
THHR-006/C01US 316188-2080	37418- 506C01US	CON	Granted	13/523710 (Patent No. 8,932,597)	14-Jun-2012	United States of America	Human M2E Peptide Immunogens		None	
THHR-006/C02US 316188-2183	N/A	CON	Pending	14/594,461	12-Jan-2015	United States of America	Human M2E Peptide Immunogens		Response to Restriction Requirement due	7/1/2015 (Initial) 11/1/15 (Final)
THHR-008/N01CN 316188-2090	37418- 508N01CN	PCT	Published	201080027170.9	23-Apr-2010	China (People's Republic)	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies		None	
THHR-008/N01TH 316188-2092	37418- 508N01TH	PCT	Pending	1101002827	23-Apr-2010	Thailand	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies	GM-CSF: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Neutralizing Antibodies: Encompasses the 1783122 antibody.	None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-008/001 US 316188-2087	37418- 508001US	ORD	Granted	12/766444 (Patent No. 8,609,101)	23-Apr-2010	United States of America	Grammacyc-Ma crophage Colony-Stimulat ing Factor (GM-CSE) Neutralizing Antibodies		None	11/11/2015 (Initial) 8/11/2016 (Final)
THHER-009/N01AU 316188-2096	37418- 509N01AU	PCT	Pending	2010249787	20-May-2010	Australia	Compositions And Methods For The Therapy And Diagnosis Of Influenza	Influenza M2e: Compositions and Methods for the Therapy and Diagnosis of Influenza: Encompasses antibodies 8i10, 21B15 23K12, 3241_G23, 3244_I10, 3243_J07, 3259_J21, 3245_O19, 3244_H04, 3136_G05, 3252_C13, 3255_J06, 3420_I23, 3139_P23, 3248_P18, 3253_P10, 3260_D19, 3362_B11, and 3242_P05. Also includes same epitopes as the 503 application.	Deadline to place application in condition for allowance	11/11/2015 (Initial) 8/11/2016 (Final)
THHER-009/N01CA 316188-2097	37418- 509N01CA	PCT	Pending	2762302	20-May-2010	Canada	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	8/20/2015 (initial) 10/20/2015 (final)
THHER-009/N01EP 316188-2098	37418- 509N01EP	PCT	Published	107325144 (EP Pub. No. 2432803)	20-May-2010	European Patent Convention	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Response to Official Action Due	10/20/2015 (final)
THHER-009/D01JP 316188-2172	N/A	DIV	Published	2014-139557	20-May-2010	Japan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-009/N01US 316188-2100	37418- 509N01US	PCT	Granted	13/321460 (Patent No. 8,858,948)	20-May-2010	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-009/C01US 316188-2175	N/A	CON	Published	14/513973	14-Oct-2014	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/N01AU 316188-2109	37418- 512N01AU	PCT	Pending	2010282415	12 Aug 2010	Australia	Compositions And Methods For The Therapy And Diagnosis Of Influenza	Influenza M2e/HA. Compositions and Methods for the Therapy and Diagnosis of Influenza. Encompasses M2e antibodies from Theracitone s. 509 application.	Deadline to place application in condition for allowance	11/11/2015 (Initial) 8/11/2016 (Final)

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-012/N01CA 316188-2110	37418- 512N01CA	PCT	Pending	27711105	12 Aug 2010	Canada	Compositions And Methods For The Therapy And Diagnosis Of Influenza	in combination with the HA antibodies of Crucell PCT application (International Patent Application PCT/EP2007/059356 (Publication No. WO 2008/028946)).	Deadline to Request Examination	8/12/2015
THHER-012/N01EP 316188-2111	37418- 512N01EP	PCT	Published	10808769.3 (EP Pub. No. 2464383)	12 Aug 2010	Europe	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/N01HK 316188-2112	37418- 512N01HK	REG	Pending	12106995.8	12 Aug 2010	Hong Kong	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/N01JP 316188-2113	37418- 512N01JP	PCT	Pending	2012-524878	12 Aug 2010	Japan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/D01JP 316188-2179	N/A	DIV	Pending	2015-30186	12 Aug 2010	Japan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/001TW 316188-2106	37418- 512001TW	ORD	Published	99127135	13-Aug-2010	Taiwan	Compositions And Methods For The Therapy And Diagnosis Of Influenza		none	
THHER-012/001US 316188-2107	37418- 512001US	ORD	Granted	12/855553 (Patent No. 8,974,788)	12-Aug-2010	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		None	
THHER-012/C01US 316188-2182	N/A	CON	Pending	14/642194	09-Mar-2015	United States of America	Compositions And Methods For The Therapy And Diagnosis Of Influenza		Response to Notice to File Missing Parts	8/19/15 (Next) 10/19/15 (Final)

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-015/N01AU 316188-2119	37418- 515N01AU	PCT	Pending	2011289275	12-Aug-2011	Australia	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof	Influenza HA: Compositions and methods for TCN-522 (3212_I12), TCN-521 (3280_D18), TCN-523 (5248_A17), TCN-563 (5237_B21), TCN-526 (5084_C17), TCN-527 (5086_C06), TCN-528 (5087_P17), TCN-529 (5297_H01), TCN-530 (5248_H10a), TCN-531 (5091_H13), TCN-532 (5262_H18), TCN-533 (5256_A17), TCN-534 (5249_B02), TCN-535 (5246_P19), TCN-536 (5095_N01), TCN-537 (3194_D21), TCN-538 (3206_O17), TCN-539 (5056_A08), TCN-540 (5060_F05), TCN-541 (5062_M11), TCN-542 (5079_A16), TCN-543 (5081_G23), TCN-544 (5082_A19), TCN-545 (5082_I15), TCN-546 (5089_L08), TCN-547 (5092_F11), TCN-548 (5092_P01), TCN-549 (5092_P04), TCN-550 (5096_F06), TCN-551 (5243_D01), TCN-552 (5249_I23), TCN-553 (5261_C18), TCN-554 (5277_M05), TCN-555 (5246_L16), TCN-556 (5089_K12), TCN-557 (5081_A04), TCN-558 (5248_H10b), TCN-559 (5097_G08), TCN-560 (5084_P10), and TCN-504 (3251_K17).	Deadline to place in condition for allowance (initial)	9/22/2015
THHER-015/N01CA 316188-2120	37418- 515N01CA	PCT	Pending	2807664	12-Aug-2011	Canada	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		Deadline to place in condition for allowance (final)	6/22/2016
THHER-015/N01EP 316188-2121	37418- 515N01EP	PCT	Published	118170927 (EP Pub. No. 2603237)	12-Aug-2011	Europe	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		Deadline to Request Examination	8/12/2016
THHER-015/N01HK 316188-2122	37418- 515N01HK	REG	Pending	13113083.6	12-Aug-2011	Hong Kong	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		None	
THHER-015/N01JP 316188-2123	37418- 515N01JP	PCT	Pending	2013-524243	12-Aug-2011	Japan	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		None	
THHER-015/001US 316188-2117	37418- 515001US	ORD	Granted	13/208754 (Patent No. 8,900,590)	12-Aug-2011	United States of America	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-015/C01US 316188-2176	N/A	ORD	Pending	14/557,515	12/02/2014	United States of America	Anti-Hemagglutinin Antibody Compositions And Methods Of Use Thereof		Response to Office Action due	9/24/2015 (Initial) 12/24/2015 (Final)
THHER-017/001US 316188-2127	37418-517001US	ORD	Published	13/418923	13 Mar 2012	United States of America	Compositions and Methods for the Therapy and Diagnosis of Influenza		Response to Office Action due	07/24/2015 (Next) 09/24/2015 (Final)
THHER-017/N01AU 316188-2129	37418-517N01AU	PCT	Pending	2012229188	13 Mar 2012	Australia	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	3/13/2017
THHER-017/N01BR 316188-2130	37418-517N01BR	PCT	Pending	BR112013023576 4	13 Mar 2012	Brazil	Compositions and Methods for the Therapy and Diagnosis of Influenza	Influenza M2e: This application combines the disclosure of (37418-503602)US, CIP), with data for the combination of an anti-M2e antibody and oseltamivir (Tamflu) for treating and preventing influenza infection.	None	
THHER-017/N01CA 316188-2131	37418-517N01CA	PCT	Pending	2829968	13 Mar 2012	Canada	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	3/13/2017
THHER-017/N01CN 316188-2132	37418-517N01CN	PCT	Pending	201280023182.3	13 Mar 2012	China	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHER-017/N01EP 316188-2133	37418-517N01EP	PCT	Pending	127099488.6 (EP Pub. No. 2685968)	13 Mar 2012	Europe	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-017/N01HN 316188-2135	37418- 517N01HN	PCT	Pending	8270/CHENP/201 3	13 Mar 2012	India	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-017/N01HL 316188-2134	37418- 517N01HL	PCT	Pending	228403	13 Mar 2012	India	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-017/N01JP 316188-2136	37418- 517N01JP	PCT	Pending	2013-558105	13 Mar 2012	Japan	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-017/N01KR 316188-2137	37418- 517N01KR	PCT	Pending	10-2013-7026811	13 Mar 2012	Korea	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	3/13/2017
THHR-017/N01MX 316188-2138	37418- 517N01MX	PCT	Pending	MEX/02013/01036 7	13 Mar 2012	Mexico	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-017/N01NZ 316188-2139	37418- 517N01NZ	PCT	Pending	615337	13 Mar 2012	New Zealand	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to place in condition for allowance (initial)	10/11/2015
THHR-017/N01SG 316188-2140	37418- 517N01SG	PCT	Pending	201306826-7	13 Mar 2012	Singapore	Compositions and Methods for the Therapy and Diagnosis of Influenza		Request Slow Track Examination	3/15/16
THHR-017/001TW 316188-2126	37418- 517001TW	ORD	Published	101108672	13 Mar 2012	Taiwan	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THERR-018/001US 316188-2143	37418- 518001US	ORD	Granted	13/372870 (Patent No. 8,916,160)	14 Feb 2012	United States of America	Compositions and Methods for the Therapy and Diagnosis of Influenza	Influenza M2e/HA: This application combines the disclosure of the 512 family (combination of Theracloine M2e antibodies with Crucell HA antibodies) with the disclosure of the 515 family (Theracloine HA antibodies).	None	
THERR-018/C01US 316188-2184	N/A	ORD	Pending	14/578777	12/22/2014	United States of America	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THERR-018/N01AU 316188-2145	37418- 518N01AU	PCT	Pending	2012217867	14 Feb 2012	Australia	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	2/14/2017
THERR-018/N01BR 316188-2146	37418- 518N01BR	PCT	Pending	BR112013020743 4	14 Feb 2012	Brazil	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THERR-018/N01CA 316188-2147	37418- 518N01CA	PCT	Pending	2827301	14 Feb 2012	Canada	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	2/14/2017
THERR-018/N01CN 316188-2148	37418- 518N01CN	PCT	Pending	201280018154.2	14 Feb 2012	China	Compositions and Methods for the Therapy and Diagnosis of Influenza		Response to Official Action due	8/6/15 (Initial) 10/6/15 (Final)
THERR-018/N01EP 316188-2149	37418- 518N01EP	PCT	Pending	12747475.7 (EP Pub. No. 2675478)	14 Feb 2012	Europe	Compositions and Methods for the Therapy and Diagnosis of Influenza		Response to Search Opinion due	12/1/15
THERR-018/N01HK 316188-2174	N/A	REG	Pending	14109187.8	14 Feb 2012	Hong Kong	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THERR-018/N01IN 316188-2151	37418- 518N01IN	PCT	Pending	2722/KOLNP/201 3	14 Feb 2012	India	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHR-018/N01IL 316188-2150	37418- 518N01IL	PCT	Pending	227947	14 Feb 2012	Israel	Compositions and Methods for the Therapy and Diagnosis of Influenza		Send art to agent	8/2/15
THHR-018/N01JP 316188-2152	37418- 518N01JP	PCT	Pending	2013-553646	14 Feb 2012	Japan	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-018/N01KR 316188-2153	37418- 518N01KR	PCT	Pending	10-2013-7024393	14 Feb 2012	Korea	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to Request Examination	2/14/2017
THHR-018/N01MX 316188-2154	37418- 518N01MX	PCT	Pending	MX/a/2013/00935 7	14 Feb 2012	Mexico	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-018/N01NZ 316188-2155	37418- 518N01NZ	PCT	Pending	614215	14 Feb 2012	New Zealand	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-018/N01SG 316188-2156	37418- 518N01SG	PCT	Pending	201306112-2	14 Feb 2012	Singapore	Compositions and Methods for the Therapy and Diagnosis of Influenza		Rely on granted counterpart & pay issue fee	2/14/2016
THHR-018/001TW 316188-2142	37418- 518001TW	ORD	Published	101104743	14 Feb 2012	Taiwan	Compositions and Methods for the Therapy and Diagnosis of Influenza		None	
THHR-019/001US 316188-2158	37418- 519001US	ORD	Granted	13/596463 (Patent No. 8,822,651)	28-Aug-2012	United States of America	Human Rhinovirus (HRV) Antidotes	HRV: Compositions, methods of making, method of using, and kits including TCN-711 (6893, E11), TCN-716 (6362, F16), TCN-717 (6358, H17), or TCN-722 (6385, L22).	None	

Coolley Docket No.	ML Docket No.	Type	Status	Serial Number	Filing Date	Country	Title	Description	Action Due	Deadline
THHER-019/C01US 316188-2173	N/A	CON	Pending	14/44948	1-Aug-2014	United States of America	Human Rhinovirus (HRV) Antibodies		Response to Restriction Requirement Due	09/03/2015 (Final)
THHER-020/001US 316188-2167	37418-520001US	ORD	Pending	14/256352	18-Apr-2014	United States of America	Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus	HCMV: Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus: Encompasses antibodies 2F10, 2M16, 2N9, 3C21, 4P12, 5P9, and 9C16. Further encompasses epitopes of the glycoprotein b (gB) envelope protein of the CMV virus, and specifically, wherein said epitope comprises the antigenic determinant 2 site 1 of gB, gp116. Application contains additional dosages and dosing regimens compared to 504 family.	Response to Restriction Requirement Due	8/11/2015 (Next) 11/11/2015 (Final)
THHER-020/001WO 316188-2164	37418-520001WO	PCT	Pending	PCT/US2014/034632	18-Apr-2014	Patent Cooperation Treaty	Compositions and Methods for the Therapy and Diagnosis of Cytomegalovirus		Deadline to enter national stage	10/19/2015
THHER-021/001US 316188-2170	37418-521001US	ORD	Pending	14/256345	18-Apr-2014	United States of America	Compositions and Methods for the Therapy and Diagnosis of Influenza	Influenza M2e: This application combines the disclosure of (37418-503002)US, CIP), with data for the combination of an anti-M2e antibody and oseltamivir (Tamflu) for treating and preventing influenza infection. Application contains additional dosages and dosing regimens compared to 517 family.	Response to Restriction Requirement	08/08/2015 (Next) 10/8/2015 (Final)
THHER-021/001WO 316188-2165	37418-521001WO	PCT	Pending	PCT/US2014/034634	18-Apr-2014	Patent Cooperation Treaty	Compositions and Methods for the Therapy and Diagnosis of Influenza		Deadline to enter national stage	10/23/2015
THHER-022/001US 316188-2169	37418-522001US	ORD	Pending	14/263305	28-Apr-2014	United States of America	Human Rhinovirus (HRV) Antibodies	HRV: Compositions, methods of making, method of using, and kits including TCN-711 (6893_E11), TCN-716 (6362_F16), TCN-717 (6358_H17), or TCN-722 (6385_L22). Application adds additional disclosure with respect to binding and activity of TCN-711 (6893_E11).	None	
THHER-022/001WO 316188-2166	37418-522001WO	PCT	Pending	PCT/US2014/035675	28-Apr-2014	Patent Cooperation Treaty	Human Rhinovirus (HRV) Antibodies		Deadline to enter national stage	11/1/2015

Client: 43831 Theravance Sciences, Inc.

Client Matter/SubCase	SubCase	Case Type	Status	Client Reference	Application Number	Patent Number	Filing Date	Issue Date	Next Action(s)	Due Date(s)
43831.00.2001		PRO	Expired		61/378,604		31-Aug-2010			
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES										
43831.00.2002		PRO	Unified							
Title: BROADLY NEUTRALIZING ANTIBODIES TO HIV THAT DEFINE A GLYCANDEPENDENT EPI TOPE PRESENT ONLY ON THE PRE-FUSION CONFORMATION OF gp41 ON CLEAVED TRIMERIC ENVELOPE										
43831.00.2013		ORD	Allowed		12/726,245		17-Mar-2010		Tax 3.5	09-Dec-2018
Title: MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY										
43831.01.2001		PRO	Expired		1382.3/IAV0020P	9,051,362	09-Jun-2015		Tax 7.5	09-Dec-2022
Title: MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY										
43831.01.2013		CON	Published		14/692,483		21-Apr-2015		File Oath/Declaration	21-Oct-2015
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES										
43831.02.2001		PRO	Expired		61/476,978		19-Apr-2011		U.S.-Application Status Check	21-Oct-2016
Title: MONOCLONAL ANTIBODIES DIRECTED AGAINST TRIMERIC FORMS OF THE HIV-1 ENVELOPE GLYCOPROTEIN WITH BROAD AND POTENT NEUTRALIZING ACTIVITY										
43831.03.2001		PRO	Expired		61/515,548		05-Aug-2011			
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES										

TRADEMARK

REEL: 005672 FRAME: 0750

Client Matter/SubCase	SubCase	Case Type	Status	Client Reference	Application Number	Filing Date	Next Action(s)	Due Date(s)
43831.04.2001		CIP	Published		13/780,776	28-Feb-2013	2 Month Due Date (Final OA) 3 Month Due Date (Final OA) Notice of Appeal 1st Extension (Final OA) 1st Extension - NOA 2nd Extension (Final OA) 2nd Extension - NOA 6 month Final - NOA 6 Month Final Date (Final OA)	13-Oct-2015 13-Nov-2015 13-Nov-2015 13-Dec-2015 13-Dec-2015 13-Jan-2016 13-Jan-2016 13-Feb-2016 13-Feb-2016
United States of America								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								
43831.22.2001		PCT	Pending		2,809,837	31-Aug-2011	Amnuty due Request Examination	31-Aug-2015 31-Aug-2016
Canada								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								
43831.22.2013		PCT	Pending		2,755,821	17-Mar-2010	Amnuty due	17-Mar-2016
Canada								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV) - NEUTRALIZING ANTIBODIES								
43831.61.2001		PCT	Pending		2011296065	31-Aug-2011	AU-Acceptance with fee Amnuty due AU-Acceptance with fee AU-Acceptance with fee AU-Acceptance with fee AU-Acceptance with fee AU-Acceptance with fee AU-Acceptance with fee AU-Acceptance with fee	20-Aug-2015 31-Aug-2015 20-Sep-2015 20-Oct-2015 20-Nov-2015 20-Dec-2015 20-Jan-2016 20-Feb-2016
Australia								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								
43831.61.2013		PCT	Pending		2010226668	17-Mar-2010	Divisional Deadline Foreign Allowance Payment Due Amnuty due	16-Oct-2015 16-Oct-2015 17-Mar-2016
Australia								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV) -NEUTRALIZING ANTIBODIES								
43831.80.2001		PCT	Abandoned		11822530.9	31-Aug-2011		
European Patent Convention								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								
43831.80.2003		DIV	Pending		14004015.5	31-Aug-2011	EP - Additional Search Fees Deadline Amnuty due	22-Aug-2015 31-Aug-2015
European Patent Convention								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								

TRADEMARK

REEL: 005672 FRAME: 0751

Client Matter/SubCase	SubCase	Case Type	Status	Client Reference	Application Number	Filing Date	Next Action(s)	Due Date(s)
43831.80.2013		PCT	Pending		10722810.8	17-Mar-2010	Annuity due	17-Mar-2016
European Patent Convention 1382.3EP/AV10029P								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV) -NEUTRALIZING ANTIBODIES								
43831.99.2001		ORD	Completed		PCT/US2011/49880	31-Aug-2011		
Patent Cooperation Treaty								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV)-NEUTRALIZING ANTIBODIES								
43831.99.2013		ORD	Completed		PCT/US2010/027695	17-Mar-2010		
Patent Cooperation Treaty TSRI382.3PCT/AVV0019								
Title: HUMAN IMMUNODEFICIENCY VIRUS (HIV) -NEUTRALIZING ANTIBODIES								

TRADEMARK

REEL: 005672 FRAME: 0752

Sort Order: by Client

Print Remarks?: No
Print Inventors?: No
Print Abstract: No
Actions Due: All

Filing Date:

From:

To:

Client Matter:

Status Code: All

Client: 43831

Case Type(s):

Status(es):

Agent:

Attorney:

Owner:

Country:

Area:

Inventor:

EXHIBIT C

Trademarks

[See attached]

Trademark	Docket Number/Subcase Country Name	Status Class(es)	Serial Number Filing Date	Registration Number/Date
I-STAR	37418-401/116 European Community	Registered 42	A0010451 27-Nov-2007	956941 27-Nov-2007
I-STAR	37418-401/226 Int'l Registration - Madrid Protocol Only	Registered 42	A0010451 27-Nov-2007	956941 27-Nov-2007
I-STAR	37418-401/032 Japan	Registered 42	A0010451 27-Nov-2007	956941 27-Nov-2007
I-STAR	37418-401/ United States of America	Registered 42	77/193531 30-May-2007	3,680,336 08-Sep-2009
THERACLONE SCIENCES	37418-404/004 Australia	Registered 5, 42	1320239 11-Sep-2009	1320239 11-Sep-2009
THERACLONE SCIENCES	37418-404/008 Canada	Registered 5, 42	1,451,308 10-Sep-2009	TMA891,074 27-Nov-2014
THERACLONE SCIENCES	37418-404/010 China (People's Republic)	Registered 5	7694951 14-Sep-2009	7694951 07-Dec-2010
THERACLONE SCIENCES	37418-404/010A China (People's Republic)	Registered 42	7694952 14-Sep-2009	7694952 07-Jan-2011
THERACLONE SCIENCES	37418-404/116 European Community	Registered 5, 42	8542888 11-Sep-2009	8542888 08-Mar-2010
THERACLONE SCIENCES	37418-404/030 India	Registered 5, 42	1861507 11-Sep-2009	1861507 11-Sep-2009
THERACLONE SCIENCES	37418-404/032 Japan	Registered	2009-69788 11-Sep-2009	5345566 13-Aug-2010
THERACLONE SCIENCES	37418-404/034 Korea, Republic of	Registered 5, 42	45-2009-0003362 14-Sep-2009	45-0032842 03-Nov-2010
THERACLONE SCIENCES	37418-404/046 New Zealand	Registered 5, 42	812579 11-Sep-2009	812579 11-Mar-2010
THERACLONE SCIENCES	37418-404/009 Switzerland	Registered 5, 42	59963/2009 11-Sep-2009	601,529 11-Jun-2010
THERACLONE SCIENCES	37418-404/066 Taiwan	Registered 5, 42	098040107 11-Sep-2009	1418226 30-Jun-2010

Trademark	Docket Number/Subcase Country Name	Status Class(es)	Serial Number Filing Date	Registration Number/Date
THERACLONE SCIENCES	37418-404/ United States of America	Registered 5	77/690467 13-Mar-2009	4,388,327 20-Aug-2013
THERACLONE SCIENCES	37418-404A/ United States of America	Registered 42	77/981342 13-Mar-2009	3,952,304 26-Apr-2011

Report Selection

- by Trademark
- by Country
- by Client
- by Owner

Report Format

- Concise
- Comprehensive

Goods

- Print
- Do Not Print

Remarks

- Print
- Do Not Print

Preview before printing

Date Range

- Filing
- Registration
- Next Renewal
- Last Update

From :

To :

Client:

Status Codes:

- Active
- Inactive
- All

Status(es):

Country:

Area:

Attorney:

Trademark:

Owner:

EXHIBIT D

Mask Works

None.